MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology
+$0.05 today
- Market cap
- $80.28M
- Beta
- 0.24
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 2.25M
Average 0.78M
MAIA Interest Income
Income earned on cash, deposits, and investments held by the company.
MAIA Biotechnology, Inc.AMEX: MAIA
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $111.76K rose 36.0% year over year, ahead of the -3.6% change in trailing-twelve-month interest income. Sequentially, it rose 51.7% from the prior quarter. Over 3 fiscal years it compounded at +451.7% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +36.0% holds above the trailing-twelve-month pace of -3.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 313.95K USD
- Year-over-year change
- -1.4%
- 4-year CAGR
- +253.4%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 313.95K | -1.4% |
| FY2024 | 2024-12-31 | 318.37K | +1052.4% |
| FY2023 | 2023-12-31 | 27.63K | +1377.4% |
| FY2022 | 2022-12-31 | 1.87K | -7.1% |
| FY2021 | 2021-12-31 | 2.01K | — |
Interest Income vs competitors
How MAIA compares with its peers on the latest reported figures
- MAIA's LTM Mar 2026 interest income of $343.53K is the 3rd highest of the 7 companies compared; the peer median is $296.15K.
- Its year-over-year change of -3.6% is the 2nd highest of 5, against a peer median of -20.0%.
- Over three fiscal years its annual growth of +451.7% compares with a peer median of +42.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $649.25K | +36.6% | +56.4% | — | |
| LTM Mar 2026 | $366K | -19.2% | +95.7% | 24.6% | |
| LTM Mar 2026 | $343.53K | -3.6% | +451.7% | — | |
| LTM Mar 2026 | $330.3K | -52.2% | +28.9% | — | |
| LTM Dec 2025 | $262K | -20.8% | -10.5% | 1.0% | |
| LTM Mar 2026 | $58K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding MAIA) | $296.15K | -20.0% | +42.7% | 12.8% | |
Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.45M | 8.93M | 11.11M | 10.01M | 14.55B |
| Selling, General & Admin | 4.29M | 6.14M | 9.07M | 6.95M | 9.72B |
| Operating Expenses | 7.79M | 16.18M | 20.18M | 16.96M | 24.27M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (11.75M) | (15.76M) | (19.77M) | (23.25M) | (22.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.79M) | (16.18M) | (20.18M) | (16.96M) | (24.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.01K | 1.87K | 27.63K | 318.37K | 313.95K |
| Interest Expense | 827.54K | 6.97K | 0 | 57 | 0 |
| Other Income / Expenses | (4.79M) | 406.92K | 409.48K | (6.3M) | 1.87M |
| Income Before Tax | (12.58M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.5M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.18) | (1.70) | (1.49) | (1.05) | (0.70) |
| EPS (Diluted) | (1.18) | (1.70) | (1.49) | (1.05) | (0.70) |
| Weighted Avg Shares | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M |
| Weighted Avg Shares (Diluted) | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M |
MAIA Biotechnology, Inc.
AMEX:MAIA
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.